Nicholas Holdgate, MD
Rheumatology · Summerville, SCNPI 1134415110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Amgen at 54.3% of the total. Reporting peaked in 2024 at $12,536 and has fallen 78.7% since, to $2,665 in 2025.
Across 633 payments — averaging $36.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- AbbVie$2K
- Johnson & Johnson$2K
- Novartis$1000
- UCB, Inc.$935
- Lilly USA, LLC$798
- plus $4K from 21 others
Across 19 payments — averaging $26,904 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$404K
- Biogen$63K
- GSK$22K
- AbbVie$20K
- Eli Lilly$2K
What the payments were for
- Consulting fees$7,95034%
- Travel & lodging$2,1279%
- Food & beverage$12,97556%
- Education$1571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 109 | $12,596 |
| AbbVie | 133 | $2,353 |
| Johnson & Johnson | 81 | $1,695 |
| Novartis | 52 | $1,000 |
| UCB, Inc. | 51 | $935 |
| Lilly USA, LLC | 40 | $798 |
| Octapharma USA, Inc. | 4 | $713 |
| E.r. Squibb & Sons, L.L.C. | 41 | $710 |
| GSK | 27 | $484 |
| AstraZeneca(2 entities) | 23 | $438 |
| Pfizer | 27 | $421 |
| Organon | 7 | $161 |
| Aurinia Pharma U.S., Inc. | 6 | $148 |
| Regeneron Healthcare Solutions, Inc. | 6 | $136 |
| Biogen | 1 | $103 |
| Genentech USA, Inc. | 5 | $94 |
| Fresenius Kabi USA, LLC | 4 | $87 |
| Boehringer Ingelheim | 4 | $79 |
| Radius Health, Inc. | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Sobi, Inc | 1 | $26 |
| Sanofi | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Sandoz | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$9,472
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$614
- TYSABRI$103
How this compares
$23,209 in reported general payments places this provider in the 85th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 16 | $104,676 |
| Orencia ClickjectAbatacept | 12 | $70,309 |
| Hydroxychloroquine Sulfate | 405 | $16,567 |
| Celecoxib | 129 | $5,293 |
| Leflunomide | 93 | $4,881 |
| MethotrexateMethotrexate Sodium | 95 | $4,391 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $3,760 |
| Prednisone | 383 | $2,010 |
| Colchicine | 28 | $1,594 |
| Duloxetine Hcl | 73 | $891 |
| Cyclobenzaprine Hcl | 82 | $815 |
| Diclofenac Sodium | 46 | $699 |
| Febuxostat | 12 | $658 |
| Azathioprine | 18 | $639 |
| Meloxicam | 137 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,353 | $104,67616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Summerville
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Bradley CollinsSummerville$6K
- Durga AdhikariSummerville$5K
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.